A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure
Completed · Phase 1 · NCT05659264
Conditions: Chronic Heart Failure
At a glance
- Research payments reported, 2025
- $52,068
- U.S. investigators named
- 3
- Sites paid
- 4
- Planned or actual enrollment
- 48
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-0184 (drug), Placebo (drug)
- Dates
- Started 2022-12-05; completion 2024-12-17
- Results posted
- Not yet
The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses at escalating dose levels of mRNA-0184.
From ClinicalTrials.gov, last updated 2025-03-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $52,068 in research payments for this study in 2025 (18 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mustafa M. Ahmed, MD Cardiology · Gainesville, FL
- Michael J. Koren, M.D. Cardiology · Gainesville, FL
- Dinesh K. Gupta, M.D. Cardiology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Jacksonville Center for Clinical Research $24,994
- Tennessee Center for Clinical $16,462
- University of Florida Contract $5,672
- University of Florida Contracts and Grants Accounting Services $4,940
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.